With it’s high prevalence and treatment costs, role as a risk factor for suicide and impact on workplace productivity, depression places an enormous burden on the healthcare system and the wider economy. Innovation that improves treatment outcomes can deliver significant and multiple benefits.
For people suffering from depression finding the right treatment that works for them can be difficult at a vulnerable time in their lives. If antidepressant medication is prescribed it typically takes 4 – 6 weeks before their doctor can detect whether the treatment is working. Up to 50% of patients fail to respond to the first antidepressant prescribed. For many people effective treatment can even take months to work.
i-Spero is a digital platform comprising both diagnostic tests that provide early indication of response to antidepressant treatment, as well as online monitoring that enables individuals to track their progress to response and remission.
More effective and integrated treatment from the outset will:
i-Spero is built on 15 years of research and development and a 3 year clinical study carried out on over 900 patients in five European countries.
i-Spero is led by an experienced management team with proven expertise in product development, clinical research, digital technology and successful entrepreneurship and is supported by an active and expert advisory panel of world renowned consultant psychiatrists, psychopharmacologists and key opinion leaders.